Introduction: The information permanently produced by population cancer registries is the input used by decision makers of the local and national health systems in order for planning cancer prevention strategies and evaluating the impact of their interventions.

Objective: To determine the incidence and mortality from cancer in the municipality of Pasto Colombia, 2013-2017 period.

Methods: Descriptive observational study of cancer morbidity and mortality. The collection and processing of information was carried out following the recommendations of the IARC. Rates were calculated by sex, age, and tumor location.

Results: The overall incidence of cancer was 3,759 cases; 1,608 in men (AAR= 169.4 cases/100,000 men-year), and 2,151 cases in women (AAR= 176.6 cases/100,000 women-year). The most frequent tumors in men were: prostate (25.9%), stomach (16.5%) and lung (4.8%); and in women: breast (19.7%), thyroid (12.2%) and cervix (10.6%). There were 2,130 cancer deaths, 934 in men (AAR=97.8 deaths/100,000 men-year) and 1,196 deaths in women (AAR=95.1 deaths/100,000 women-year). The main causes of mortality in men were tumors of the stomach (24.8%), prostate (12.8%) and lung (7.5%). In women: breast (12.2%), stomach (11.6%) and cervix (10.0%).

Conclusion: The five-year follow-up of cancer burden indicators allows to make comparisons at both national and international levels, in order to provide the basis for planning and evaluating the implementation of public health policies; especially those related to the prevention and care of the most common causes of morbidity and mortality from cancer in Pasto-Colombia.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9651136PMC
http://dx.doi.org/10.25100/cm.v53i1.4952DOI Listing

Publication Analysis

Top Keywords

mortality cancer
12
cancer
9
incidence mortality
8
colombia 2013-2017
8
morbidity mortality
8
women breast
8
cancer pasto
4
pasto municipality
4
municipality colombia
4
2013-2017 introduction
4

Similar Publications

TRPV4 as a Novel Regulator of Ferroptosis in Colon Adenocarcinoma: Implications for Prognosis and Therapeutic Targeting.

Dig Dis Sci

January 2025

Ningxia Medical University, Xing Qing Block, Shengli Street No.1160, Yin Chuan City, 750004, Ningxia Province, People's Republic of China.

Background: Colon adenocarcinoma (COAD) is a leading cause of cancer-related mortality worldwide. Transient receptor potential vanilloid 4 (TRPV4), a calcium-permeable non-selective cation channel, has been implicated in various cancers, including COAD. This study investigates the role of TRPV4 in colon adenocarcinoma and elucidates its potential mechanism via the ferroptosis pathway.

View Article and Find Full Text PDF

Purpose: Carcinoembryonic antigen (CEA) is an important prognostic factor for rectal cancer. This study aims to introduce a novel cutoff point for CEA within the normal range to improve prognosis prediction and enhance patient stratification in rectal cancer patients.

Methods: A total of 316 patients with stages I to III rectal cancer who underwent surgical tumor resection were enrolled.

View Article and Find Full Text PDF

Progress report on multiple endocrine neoplasia type 1.

Fam Cancer

January 2025

Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Multiple endocrine neoplasia type 1 (MEN1) syndrome is an autosomal dominant disorder caused by a germline pathogenic variant in the MEN1 tumor suppressor gene. Patients with MEN1 have a high risk for primary hyperparathyroidism (PHPT) with a penetrance of nearly 100%, pituitary adenomas (PitAd) in 40% of patients, and neuroendocrine neoplasms (NEN) of the pancreas (40% of patients), duodenum, lung, and thymus. Increased MEN1-related mortality is mainly related to duodenal-pancreatic and thymic NEN.

View Article and Find Full Text PDF

Purpose: Patients with partial or complete DPD deficiency have decreased capacity to degrade fluorouracil and are at risk of developing toxicity, which can be even life-threatening.

Case: A 43-year-old man with moderately differentiated rectal adenocarcinoma on capecitabine presented to the emergency department with complaints of nausea, vomiting, diarrhea, weakness, and lower abdominal pain for several days. Laboratory findings include grade 4 neutropenia (ANC 10) and thrombocytopenia (platelets 36,000).

View Article and Find Full Text PDF

Venetoclax plus azacitidine represents a key advance for older, unfit patients with acute myeloid leukemia (AML). The chemotherapy and venetoclax in elderly AML trial (CAVEAT) was first to combine venetoclax with intensive chemotherapy in newly diagnosed patients ≥65 years. In this final analysis, 85 patients (median age 71 years) were followed for a median of 41.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!